이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

S. Korean Celltrion’s biosimilar Remsima Q1 sales in U.S. reach $17mn

Collected: 2017.05.05

Distributed: 2017.05.10

Source: Go Direct

South Korea’s biopharmaceutical firm Celltrion Inc.’s first biosimilar Remsima has sold $17 million worth volume in the U.S. from last November to March this year.

According to the first-quarter earnings report from Pfizer Inc. responsible for marketing and sales of Remsima in the U.S. and Europe on Tuesday, it sold around $17 million worth of Remsima available under the name of Inflectra in the U.S. from November.

Remsima, which goes by the name of Inflectra in the U.S., is a cheaper biosimilar version of Johnson & Johnson’s Remicade (infliximab) that is effective for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, pediatric and adult Crohn’s disease, psoriasis, and psoriatic arthritis.

Remsima largely contributed to the first-quarter revenue of its U.S. retailer Pfizer, making $78 million of the firm’s total global biosimilar sales of $105 million. The firm noted in its earnings conference call Tuesday it saw an on-month operation gain of 62 percent from selling biosimilars, “driven by Inflectra (Remsima) in certain developed Europe markets and in the U.S.” The firm said it remains “very positive about the opportunity for Inflectra in the U.S.,” citing positive customer reception in the early stages of the launch of the drug.

By Shin Chan-ok

List

Previous: S. Korea, Finland to discuss addition of direct flights between two countries

Next: S. Korea, Japan and China pledge to fight against protectionism